Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Describe the biology of and rationale for targeting NSCLC harboring NTRK fusions
Identify patients with NSCLC who should be tested for NTRK fusions with established and emerging biomarker assays
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York
Associate Scientific Director
Senior Clinical Editor
Associate Director, Scientific Services
Associate Director, Educational Strategy
Senior Director, Educational Strategy
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians and other healthcare providers who care for patients with lung cancer.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 28, 2021, through January 27, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Phase I/II trial of mobocertinib for EGFR ex20ins+ advanced NSCLC in cohort of patients with disease progression after initial disease control on EGFR TKI therapy, from WCLC 2021 by Clinical Care Options (CCO)
Initial analysis of amivantamab in patients with METex14+ metastatic or unresectable NSCLC from phase I CHRYSALIS trial, from WCLC 2021 as reported by Clinical Care Options (CCO)
Downloadable summary slideset from a live CCO Webinar on immunotherapy for the treatment of patients across the spectrum of NSCLC
3-year update of CASPIAN showed sustained survival benefit of adding durvalumab to platinum-etoposide for first-line treatment in extensive-stage SCLC, presented at ESMO 2021 and reported by Clinical Care Options (CCO)